ED injections: how intracavernosal therapy works

Injection therapy for erectile dysfunction means injecting medicine directly into the erectile tissue of the penis, where it relaxes smooth muscle and widens blood vessels so blood can fill the tissue.

It sounds worse than most people find it. It is also one of the older and better established options in this field, and it typically comes up when tablets have not worked.

The category, and the long record

The clinical term is intracavernosal injection, often shortened to ICI. It has been in use since the early 1980s, and a 2024 review in Sexual Medicine Reviews traces four decades of that history.

Long-term outcome studies exist. A 2019 study in the International Journal of Impotence Research examined efficacy and patient satisfaction with long-term injection therapy. There is a systematic review of its use in men with spinal cord injury, and published work on side effects and why people discontinue.

The important structural point: this is an established therapy with decades of published use, which is a different situation from a newer injectable marketed for the same problem.

What gets injected

Two broad options.

Single-agent alprostadil. There are FDA approved alprostadil products for this use.

Combination mixtures, commonly called bimix or trimix. These combine alprostadil with papaverine, and in trimix also phentolamine. Because each agent works differently, the combination can produce an effect at lower doses of each.

Combination mixtures are compounded, not FDA approved. That is a meaningful distinction and we cover it separately on the trimix page. Newer combinations are still being studied, including a 2025 trial in the Journal of Sexual Medicine of aviptadil with phentolamine for refractory ED.

Who it tends to be for

Generally people for whom oral medicines have not worked, are not tolerated, or are not suitable. That commonly includes men after prostate surgery, men with diabetes-related ED, and men with spinal cord injury, for whom there is a dedicated systematic review.

Whether it is right for you is a clinical decision, and it depends on your history and what else you take. This page is not that decision.

What it is actually like

Practical things worth knowing in advance, because most pages skip them.

The first dose is usually given in a clinic. That is not bureaucracy. Dose finding matters and a first dose is a supervised event for a reason.

The needle is very fine and the injection is into the side of the shaft, not the tip or the vein. Your prescriber will show you.

It works quickly, generally within minutes rather than the wait associated with tablets.

It is not automatic. Technique, dose and site all matter, and most people need a session or two to get comfortable.

The risks, stated plainly

Prolonged erection is the one to understand before you start. An erection that will not subside is a medical emergency, because prolonged loss of blood flow can cause permanent damage. Know in advance what the threshold is, who to call, and where to go. Ask your prescriber to give you that plan in writing.

Pain or aching at the injection site or in the shaft is reported, more commonly with alprostadil.

Scarring or fibrosis with repeated use over time.

Bruising or bleeding at the injection site.

Discontinuation is common. Published work on ICI specifically looks at dropout rates. People stop for a mix of reasons including inconvenience, cost, discomfort and partner factors. That is worth knowing before you commit, and it is not a personal failure if it happens.

Cost and supply

Compounded mixtures are typically bought through a compounding pharmacy, which raises the questions on our trimix page: which pharmacy, what concentration, how stored, and what happens if the formulation changes.

Ask for the total monthly cost at your expected frequency, not the price of one vial.

The thing worth asking about regardless

Erectile dysfunction is an independent predictor of future cardiovascular events, per a 2018 analysis in Circulation from the Multi-Ethnic Study of Atherosclerosis. Injection therapy treats the symptom well. It does not investigate why the symptom appeared.

If nobody has assessed your blood pressure, lipids, glucose and medications, that is a separate and arguably more important conversation.

What to ask

• Will my first dose be supervised?
• Exactly what is in my prescription and at what concentration?
• What is my plan if an erection lasts too long, and who do I call?
• How often is it safe for me to use this?
• What is the total monthly cost at my expected frequency?
• Has anyone looked at why I have this problem, not just how to treat it?

Sources

• A comprehensive history of injection therapy for erectile dysfunction, 1982-2023. Sexual Medicine Reviews, 2024. doi:10.1093/sxmrev/qeae020
• Long-term intracavernosal injection therapy: treatment efficacy and patient satisfaction. International Journal of Impotence Research, 2019. doi:10.1038/s41443-019-0186-z
• Intracavernous injections in spinal cord injured men with erectile dysfunction: a systematic review. Sexual Medicine Reviews, 2016. doi:10.1016/j.sxmr.2016.02.005
• Intracavernosal injection therapy: efficacy, side effects and dropouts. Journal of Sexual Medicine, 2018. doi:10.1016/j.jsxm.2018.04.618
• An empirical versus risk-based approach algorithm to intracavernosal injection therapy: a prospective study. Sexual Medicine, 2017. doi:10.1016/j.esxm.2016.08.001
• Intracavernosal injection of aviptadil and phentolamine for refractory erectile dysfunction. Journal of Sexual Medicine, 2025. doi:10.1093/jsxmed/qdaf067
• Erectile Dysfunction as an Independent Predictor of Future Cardiovascular Events: The Multi-Ethnic Study of Atherosclerosis. Circulation, 2018. doi:10.1161/CIRCULATIONAHA.118.033990

How we verify: see /how-we-verify.

Keep reading

What trimix is and what compounded means for it, at /guides/trimix.

A non-drug option with a solid evidence base, at /guides/ed-vacuum-pump.